Save up to 30% on Elsevier print and eBooks with free shipping. No promo code needed.
Save up to 30% on print and eBooks.
Coronavirus Drug Discovery
Volume 2: Antiviral Agents from Natural Products and Nanotechnological Applications
1st Edition - July 7, 2022
Editor: Chukwuebuka Egbuna
Language: English
Paperback ISBN:9780323955744
9 7 8 - 0 - 3 2 3 - 9 5 5 7 4 - 4
eBook ISBN:9780323955751
9 7 8 - 0 - 3 2 3 - 9 5 5 7 5 - 1
Coronavirus Drug Discovery, Volume Two: Antiviral Agents from Natural Products and Nanotechnological Applications presents detailed information on drug discovery against COVID-19.…Read more
Purchase options
LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Coronavirus Drug Discovery, Volume Two: Antiviral Agents from Natural Products and Nanotechnological Applications presents detailed information on drug discovery against COVID-19. Sections in this volume present chapters that focus on the various antiviral agents from natural products that have the propensity to be used as chemical scaffolds for the development of drugs against COVID-19. Also captured are the dietary sources of antioxidant bioactives that may help boost the immune system for the management of COVID-19. Other chapters describe the application of nanotechnology for efficient and effective delivery of drugs against COVID-19.
Written by global team of experts, this book is an excellent resource for drug developers, medicinal chemists, pharmaceutical companies in R&D and research institutes in both academia and industry.
Presents the various antiviral bioactive compounds from natural products
Discusses the roles of antioxidant in the prevention and management of COVID-19
Details the application of nanotechnology for efficient and effective drug delivery
Researchers in organic and medicinal chemistry including drug developers and medicinal chemists, virologists, toxicologists, analytical chemists.Researchers in pharmaceutical and biotech industries
Cover image
Title page
Table of Contents
Copyright
List of contributors
Part I. Antiviral agents from natural products
Chapter 1. COVID-19 management and phytomedicine interventions: potentials and safety considerations
1.1. Introduction
1.2. Modes of transmission
1.3. Understanding the pathophysiology of the COVID-19 infection
1.4. Priming the immune system: effect of immune boosters on susceptibility to COVID-19 infection
1.5. Reduction of the viral load: potential utilization of medicinal plants
1.6. Safety issues in the consideration of phytomedicine interventions in the management of COVID-19
1.7. Future projections
1.8. Conclusion
Chapter 2. Antiviral effects of medicinal plants and their active phytochemical constituents against respiratory diseases and associated biological functions
2.1. Introduction
2.2. Respiratory viral infections
2.3. Viral respiratory diseases and their pathogens
2.4. Plant species used in treatment of viral respiratory infections
2.5. Conclusions and future perspectives
Chapter 3. Herbs and drugs in clinical trials for coronavirus treatments
3.1. Introduction
3.2. Coronavirus
3.3. Symptoms and management of coronavirus disease
3.4. Clinical trials for coronavirus treatments
3.5. Future projections
3.6. Conclusion
Chapter 4. Bioactive compounds and herbal preparations implicated in the treatment of SARS-CoV-2
4.1. Introduction
4.2. Treatment protocols
4.3. Herbal therapies
4.4. Limitations of the use of herbal medicine
4.5. Future perspectives
4.6. Conclusion
Chapter 5. Roles of antioxidants in the prevention and management of coronavirus disease 2019
5.1. Introduction
5.2. Oxidative stress and viral infections
5.3. Immune systems and viral infections
5.4. Antioxidants supporting optimal immune function
5.5. Antioxidants against viral diseases
5.6. Phytochemicals for boosting immunity against coronaviruses
5.7. Peptide-derived antioxidant components
5.8. Micronutrients against viral diseases
5.9. Future projections
5.10. Conclusion
Chapter 6. Food sources of natural antioxidants for body defense against SARS-CoV-2
6.1. Introduction
6.2. The role of nutrition in the strengthening of the immune system against SARS-CoV-2
6.3. Antioxidants, nutrition micro-ingredients necessary to fight infection
6.4. Plants with medical properties
6.5. Use of plants as a source of natural antioxidants
6.5. African origin of sources of vitamins against SARS-CoV-2
6.6. Future perspectives
6.7. Conclusion
Chapter 7. Nutritional management against severe acute respiratory syndrome coronavirus-2 infection
7.1. Introduction
7.2. Nutritional requirements
7.3. Basic macronutrient need
7.4. Micronutrients
7.5. Nutritional supplements
7.6. Future perspectives
7.7. Conclusion
Chapter 8. Plants sources of vitamins against SARS-CoV-2
8.1. Introduction
8.2. Plants as a valuable source of vitamins and other bioactives
8.3. Future perspectives
8.4. Conclusion
Chapter 9. Microorganisms as potential source of drug for SARS-CoV-2 (COVID-19): antimicrobial drugs-ivermectin, azithromycin
9.1. Introduction
9.2. Prevention and control
9.3. Vaccines against COVID-19
9.4. Suggestive approaches against SARS-CoV-2
9.5. The antimicrobials: ivermectin and azithromycin
9.6. Future prospects
9.7. Conclusion
Chapter 10. Drug discovery opportunities from traditional practices against SARS-CoV-2: Madagascar COVID organics and the use of mugwort plant
10.1. Introduction
10.2. Treatment options using conventional medicine
10.3. Management of COVID-19 from traditional practices
10.4. Antiviral compounds from medicinal plants
10.5. Madagascar COVID organics and the use of mugwort plant against SARS-CoV-2
10.6. Future perspectives
10.7. Conclusion
Chapter 11. Marine organisms as a potential source of antiviral drugs for the treatment of coronavirus infections and other viral diseases
11.1. Introduction
11.2. Compounds from marine organisms with antiviral activity and their sources
11.3. Marine organisms as potential sources of antiviral agents against coronavirus
11.4. Marine organisms as potential sources of antiviral agents against COVID-19
11.5. Future perspectives
11.6. Conclusion
Chapter 12. Antiviral potentials of marine algal bioactive compounds for coronavirus drug discovery
12.1. Introduction
12.2. Bioactive compounds from algae
12.3. Future projections
12.4. Conclusion
Part II. Application of nanotechnology in coronavirus drug discovery
Chapter 13. Application of nanotechnology in drug development and delivery for SARS-CoV-2 treatment
13.1. Introduction
13.2. Nanosized drug carriers
13.3. Nano-based drug delivery systems
13.4. Drug targeting
13.5. Mechanism of action of COVID-19
13.6. Current treatment methods for COVID-19
13.7. Intranasal drug delivery using nanocarriers
13.8. Nanoparticles-based treatment modalities
13.9. Future projections
13.10. Conclusion
Chapter 14. Nanocarriers as potential and effective delivery tool for COVID-19 drugs
14.1. Introduction
14.2. Nanotechnology approach
14.3. Nanocarriers as an effective delivery tool
14.4. Theranostic nanocarriers
14.5. Virus-like NPs
14.6. Self-assembling protein NPs (SAPNPs)
14.7. Nano biosensors
14.8. Conclusion
Chapter 15. Nanomaterials for the rapid diagnosis of SARS-CoV-2 and other viral infections
15.1. Introduction
15.2. Nanomaterials in the diagnosis of microbial infections
15.3. Nanomaterials for the diagnosis of viral infections
15.4. Nanomaterials for the diagnosis of pandemic viral infections
15.5. The necessity to develop rapid diagnostic methods
15.6. Nanomaterials for COVID-19 diagnosis
15.7. Mechanism of COVID-19 diagnosis using nanomaterials
15.8. Conclusion
Chapter 16. Nanocarriers as delivery tool for COVID-19 drugs
16.1. Introduction
16.2. Repurposing of drugs and their nanopotentiation
16.3. Nanopotentiation of potential drugs against COVID-19
16.4. Regulatory aspects of nanopotentiated products for COVID-19
16.5. Future perspective
16.6. Conclusion
Chapter 17. Plant-based nanoformulations for human viral diseases: an emphasis on COVID-19
17.1. Introduction
17.2. Nanoparticles and their mode of viral inhibition
17.3. Plant-based nanoformulations
17.4. Possible mode of action of nanoparticles against SARS-CoV-2
17.5. Recent developments in nanoformulations for tackling 2019-nCoV
17.6. Future projections
17.7. Conclusion
Index
No. of pages: 382
Language: English
Edition: 1
Published: July 7, 2022
Imprint: Elsevier
Paperback ISBN: 9780323955744
eBook ISBN: 9780323955751
CE
Chukwuebuka Egbuna
Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.
Affiliations and expertise
Chartered Chemist and Academic Researcher, Nigeria